Ablation Reboots the Response in Advanced Hepatocellular Carcinoma With Stable or Atypical Response During PD-1 Therapy: A Proof-of-Concept Study

Ablation Reboots the Response in Advanced Hepatocellular Carcinoma With Stable or Atypical Response During PD-1 Therapy: A Proof-of-Concept Study

Background: The anti-programmed cell death protein-1 (PD-1) inhibitor is one of the second-line therapies for advanced hepatocellular carcinoma (HCC) after sorafenib failure. The goal of this study is to evaluate the feasibility and safety of ablation on the tumor in patients with advanced HCC who h...

Full description

Bibliographic Details
Main Authors: Ning Lyu, Yanan Kong, Xiaoxian Li, Luwen Mu, Haijing Deng, Huiming Chen, Meng He, Jinfa Lai, Jibin Li, Hailin Tang, Youen Lin, Ming Zhao
Format: Article
Language:English
Published: Frontiers Media S.A. 2020-10-01
Series:Frontiers in Oncology
Subjects:
hepatocellular carcinoma
anti-PD-1 mAbs
thermal ablation
nivolumab
pembrolizumab
Online Access:https://www.frontiersin.org/article/10.3389/fonc.2020.580241/full

Internet

https://www.frontiersin.org/article/10.3389/fonc.2020.580241/full

Similar Items